Maybe, but if PGE2 signaling is disrupted in non-cartilage tissues, it could promote abnormal growth or inflammation. For example, PGE2 has complex roles in cancer and fibrosis. And if the drug isn’t perfectly specific, it might inhibit other enzymes or pathways. This is because 15-PGDH is active in other tissues (e.g., liver, muscle, bone). Inhibiting it systemically might affect these tissues, though the study suggests localized joint injection could minimize this I suppose…
Yeah but while PGE2 promotes cartilage repair, it also plays roles in inflammation, fever, and gastrointestinal issues. If PGE2 levels rise too high or in the wrong context, it could cause unwanted inflammation or side effects similar to NSAIDs (e.g. stomach irritation).
Maybe, but if PGE2 signaling is disrupted in non-cartilage tissues, it could promote abnormal growth or inflammation. For example, PGE2 has complex roles in cancer and fibrosis. And if the drug isn’t perfectly specific, it might inhibit other enzymes or pathways. This is because 15-PGDH is active in other tissues (e.g., liver, muscle, bone). Inhibiting it systemically might affect these tissues, though the study suggests localized joint injection could minimize this I suppose…